<DOC>
	<DOCNO>NCT00321477</DOCNO>
	<brief_summary>This Phase IIa study evaluate efficacy , safety tolerability GW679769 v placebo symptom urgency urge incontinence , frequency nocturia associate overactive bladder woman .</brief_summary>
	<brief_title>A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder</brief_title>
	<detailed_description>A Twelve-Week Randomized , Double-Blind , Placebo-Controlled , Parallel Group , Forced Titration , Proof Concept Study Assess Efficacy , Safety Tolerability well Pharmacokinetic Profile 60 mg 120 mg GW679769 administer daily v Placebo Women Overactive Bladder</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<criteria>Female subject overactive bladder symptom urgency urge incontinence frequency may associate nocturia without bladder pain . Must pregnant . Must childbearing potential willing use specific barrier method outline protocol . Body weight range = 45 kg &lt; 100 kg . Stage III/IV pelvic organ prolapse without cystocele . History interstitial cystitis bladder relate pain . Subjects stress incontinence mixed incontinence stress incontinence predominant component base prior history . History pelvic prolapse repair ( cystocele rectocele ) urethral diverticulectomy within six month screen . Subjects urinary incontinence due cause detrusor activity ( e.g. , overflow incontinence ) . Nocturnal enuresis . Urinary retention , evidence poor detrusor function . History prior antiincontinence surgery . History radiation cystitis history pelvic irradiation . Electrostimulation , biofeedback , bladder training therapy ( behavioral therapy ) previous month prior screening , intention initiate therapy study . Pessaries implant also exclude . Participated clinical trial investigation drug may affect urinary function within 3 month enrollment study . Received investigational product within 30 day enrollment study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Overactive Bladder</keyword>
</DOC>